Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma-Reference-Cited by-同舟云学术

Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma

Published:2014-01-10 Issue:6167 Volume:343 Page:189-193
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Johnson Brett E.¹,Mazor Tali¹,Hong Chibo¹,Barnes Michael²,Aihara Koki³⁴,McLean Cory Y.¹,Fouse Shaun D.¹,Yamamoto Shogo³,Ueda Hiroki³,Tatsuno Kenji³,Asthana Saurabh⁵⁶,Jalbert Llewellyn E.⁷,Nelson Sarah J.⁷⁸,Bollen Andrew W.²,Gustafson W. Clay⁹,Charron Elise¹⁰,Weiss William A.¹⁹¹⁰,Smirnov Ivan V.¹,Song Jun S.¹¹¹²,Olshen Adam B.⁶¹¹,Cha Soonmee¹,Zhao Yongjun¹³,Moore Richard A.¹³,Mungall Andrew J.¹³,Jones Steven J. M.¹³,Hirst Martin¹³,Marra Marco A.¹³,Saito Nobuhito⁴,Aburatani Hiroyuki³,Mukasa Akitake⁴,Berger Mitchel S.¹,Chang Susan M.¹,Taylor Barry S.⁵⁶¹¹,Costello Joseph F.¹

Affiliation:

1. Department of Neurological Surgery, University of California, San Francisco, CA 94158, USA.

2. Department of Pathology, University of California, San Francisco, CA 94158, USA.

3. Genome Science Laboratory, Research Center for Advanced Science and Technology, University of Tokyo, Meguro-ku, Tokyo 153-8904, Japan.

4. Department of Neurosurgery, University of Tokyo, Bunkyo-ku, Tokyo 113-8655, Japan.

5. Department of Medicine, University of California, San Francisco, CA 94158, USA.

6. Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94158, USA.

7. Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA 94158, USA.

8. Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94158, USA.

9. Department of Pediatrics, University of California, San Francisco, CA 94158, USA.

10. Department of Neurology, University of California, San Francisco, CA 94158, USA.

11. Department of Epidemiology and Biostatistics, University of California, San Francisco, CA 94158, USA.

12. Institute for Human Genetics, University of California, San Francisco, CA 94158, USA.

13. Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC V5Z 4E6, Canada.

Abstract

Back with a Vengeance After surgery, gliomas (a type of brain tumor) recur in nearly all patients and often in a more aggressive form. Johnson et al. (p. 189 , published online 12 December 2013) used exome sequencing to explore whether recurrent tumors harbor different mutations than the primary tumors and whether the mutational profile in the recurrences is influenced by postsurgical treatment of patients with temozolomide (TMZ), a chemotherapeutic drug known to damage DNA. In more than 40% of cases, at least half of the mutations in the initial glioma were undetected at recurrence. The recurrent tumors in many of the TMZ-treated patients bore the signature of TMZ-induced mutagenesis and appeared to follow an evolutionary path to high-grade glioma distinct from that in untreated patients.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference60 articles.

1. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine

2. Clonal evolution in cancer

3. Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia

4. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

5. Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

Cited by 1121 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The potential of mesenchymal stem cell coexpressing cytosine deaminase and secretory IL18-FC chimeric cytokine in suppressing glioblastoma recurrence;International Immunopharmacology;2024-12

2. BMS345541 is predicted as a repurposed drug for the treatment of TMZ-resistant Glioblastoma using target gene expression and virtual drug screening;Cancer Genetics;2024-11

3. Systematic Reversal of Drug Resistance in Cancer;Targets;2024-09-13

4. Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape;Frontiers in Immunology;2024-09-13

5. Comprehensive understanding of the adverse effects associated with temozolomide: a disproportionate analysis based on the FAERS database;Frontiers in Pharmacology;2024-08-23